240 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author오기욱-
dc.date.accessioned2016-12-09T01:33:53Z-
dc.date.available2016-12-09T01:33:53Z-
dc.date.issued2015-05-
dc.identifier.citationSTEM CELLS TRANSLATIONAL MEDICINE, v. 4, Page. 590-597en_US
dc.identifier.issn2157-6564-
dc.identifier.issn2157-6580-
dc.identifier.urihttp://stemcellstm.alphamedpress.org/content/4/6/590-
dc.identifier.urihttp://hdl.handle.net/20.500.11754/24761-
dc.description.abstractStem cell therapy is an emerging alternative therapeutic or disease-Modifying strategy for amyotrophic lateral sclerosis (ALS). The aim of this open-label phase I clinical trial was to evaluate the safety of two repeated intrathecal injections of autologous. bone marrow (BM)-derived mesenchymal stromal cells (MSCs) in ALS patients. Eight patients with definite or probable ALS were enrolled. After a 3-month lead-in period, autologous MSCs were isolated two times from the BM at an interval of 26 days and were then expanded in vitro for 28 days and suspended in autologous cerebrospinal fluid. Of the 8 patients, 7 received 2 intrathecal injections of a utologous MSCs (1 x 10(6) cells per kg) 26 days apart. Clinical or laboratory measurements were recorded to evaluate the safety 12 months after the first MSC injection. The ALS Functional Rating Scale-Revised (ALSFRS-R), the Appel ALS score, and forced vital capacity were used to evaluate the patients' disease status. One patient died before treatment and was withdrawn from the study. With the exception of that patient, no-serious adverse events were observed during the 12-month follow-up period. Most of the adverse events were self-limited or subsided after supportive treatment within 4 days. Decline in the ALSFRS-R score was not accelerated during the 6-month follow-up period. Two repeated intrathecal injections of autologous MSCs were safe and feasible throughout the duration of the 12-month follow-up period.en_US
dc.description.sponsorshipThis study was supported by grants from the Korea Healthcare Technology R&D Project of the Ministry for Health & Welfare Affairs, Republic of Korea (HI10C1673). This study would not have been possible without the participation of the patients and their-families. We also thank the ALS nurse specialists at the Hanyang ALS Clinic (Ji Won An, Juyeon Oh, Hanna Lim, and Bo Kyeong Hwang) for their helpful support. K.-W.O. and S.H.K. had full access to all the data in this study and take responsibility for the integrity of the data and the accuracy of the data analysis.en_US
dc.language.isoenen_US
dc.publisherALPHAMED PRESSen_US
dc.subjectAmyotrophic lateral sclerosisen_US
dc.subjectClinical trialsen_US
dc.subjectMesenchymal stromal cellsen_US
dc.subjectIntrathecalen_US
dc.titlePhase I Trial of Repeated Intrathecal Autologous Bone Marrow-Derived Mesenchymal Stromal Cells in Amyotrophic Lateral Sclerosisen_US
dc.typeArticleen_US
dc.relation.volume4-
dc.identifier.doi10.5966/sctm.2014-0212-
dc.relation.page590-597-
dc.relation.journalSTEM CELLS TRANSLATIONAL MEDICINE-
dc.contributor.googleauthorOh, Ki-Wook-
dc.contributor.googleauthorMoon, Chanil-
dc.contributor.googleauthorKim, Hyun Young-
dc.contributor.googleauthorOh, Sung-Il-
dc.contributor.googleauthorPark, Jinseok-
dc.contributor.googleauthorLee, Jun Ho-
dc.contributor.googleauthorChang, In Young-
dc.contributor.googleauthorKim, Kyung Suk-
dc.contributor.googleauthorKim, Seung Hyun-
dc.relation.code2015006228-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidkiwook-oh-
dc.identifier.orcidhttp://orcid.org/0000-0001-6011-629X-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE